Other News

MyoKardia Appoints William Fairey as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.  Mr. Fairey will have […]

New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session

BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 23, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced that new data showing the reduction in total major adverse cardiovascular (i.e., ischemic) events shown in the landmark REDUCE-IT™ cardiovascular outcomes trial has been accepted for […]

InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019

TEL AVIV, Israel, Jan. 23, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard™ EPS were presented at LINC 2019, […]

Philips and the American Heart Association join together to increase global survival rates of Sudden Cardiac Arrest

AMSTERDAM and DALLAS, Jan. 23, 2019 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the American Heart Association, the world’s leading voluntary health organization devoted to a world of longer, healthier lives, today announced a collaboration to increase sudden cardiac arrest (SCA) survival rates in densely populated cities around the world. […]

Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

IRVINE, Calif.–(BUSINESS WIRE)–Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended by its Notified Body, GMED, following a voluntary recall and Field Safety […]

Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reducer implantation

VANCOUVER, Jan. 23, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Journal of the American College of Cardiology: […]

DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders

MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) — DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic Stroke” in the peer reviewed journal, Therapeutic Advances in Neurological Disorders (“TAND”). The paper summarizes the mechanistic rationale for using KLK1 to treat patients with […]

Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB

DUBLIN and LEIPZIG, Germany – January 22, 2019 – Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Outcomes from the IN.PACT DCB Paclitaxel Safety Analysis, an independent, patient-level survival […]

InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology

TEL AVIV, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled, “Initial Clinical Study of the New […]